Treatment of secondary hyperparathyroidism in patients with CKD stages 3 or 4 and vitamin D deficiency should aim to control parathyroid hormone levels early in the disease course, while parathyroid cells are still responsive to physiological 1,25(OH)2D signalling. The gene discussed is PTH; the disease is vitamin D deficiency.